FDA Probes Roche, Novartis Drugs' Link To Disorder
The FDA is reviewing data from Roche Holding AG about instances of progressive multifocal leukoencephalopathy, or PML, in patients who have taken the company's transplant drug CellCept. The FDA has requested similar information on Novartis AG's drug Myfortic.
PML, caused by a virus that damages the nervous system, usually develops in patients who...
To view the full article, register now.